GLP1R and obesity disorder: GLP-1 receptor agonists (e.g., liraglutide, semaglutide, dulaglutide) reducemajor adverse cardiovascular events (MACE), particularly in patients with type 2diabetes (T2DM) and obesity, who are at high cardiovascular risk.